Q3 2024 · 13F-HR
ACUTA CAPITAL PARTNERS, LLCholdings as filed
Filed 2024-11-14 · accession 0001104659-24-118283
$123.5M
Reported value
41
Positions
2024-09-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 92243G108 | PCVX | VAXCYTE INC | $15.5M | 12.5% | 135,400 | Common | SOLE |
| 67576A100 | OCUL | OCULAR THERAPEUTIX INC | $10.4M | 8.39% | 1,190,071 | Common | SOLE |
| 89157D105 | TRML | TOURMALINE BIO INC | $8.5M | 6.92% | 332,095 | Common | SOLE |
| 457669307 | INSM | INSMED INC | $7.8M | 6.36% | 107,500 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $7.6M | 6.13% | 296,368 | Common | SOLE |
| 22663K107 | CRNX | CRINETICS PHARMACEUTICALS IN | $6.7M | 5.45% | 131,700 | Common | SOLE |
| 03940C100 | ACLXGBX | ARCELLX INC | $5.2M | 4.20% | 62,100 | Common | SOLE |
| 589492107 | MREO | MEREO BIOPHARMA GROUP PLC | $5.2M | 4.20% | 1,260,700 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $4.9M | 3.97% | 108,000 | Common | SOLE |
| 877619106 | TSHA | TAYSHA GENE THERAPIES INC | $4.3M | 3.45% | 2,118,992 | Common | SOLE |
| 880881107 | 430 | TERNS PHARMACEUTICALS INC | $4.1M | 3.29% | 487,000 | Common | SOLE |
| 50127T109 | KURA | KURA ONCOLOGY INC. COMMON STOCK | $3.8M | 3.12% | 197,000 | Common | SOLE |
| 00032Q104 | WHWK | AADI BIOSCIENCES INC | $3.8M | 3.09% | 1,849,402 | Common | SOLE |
| 77313F106 | RCKT | ROCKET PHARMACEUTICALS INC | $3.5M | 2.84% | 190,000 | Common | SOLE |
| 74006W207 | PRAX | PRAXIS PRECISION MEDICINES I | $3.3M | 2.68% | 57,500 | Common | SOLE |
| 04016X101 | ARGX | ARGENX SE | $3.2M | 2.59% | 5,900 | Common | SOLE |
| 04351P101 | ASNDUSD | ASCENDIS PHARMA A/S | $3.1M | 2.54% | 21,000 | Common | SOLE |
| 20451W101 | CMPS | COMPASS PATHWAYS PLC | $2.4M | 1.97% | 386,500 | Common | SOLE |
| 59045L106 | — | MERSANA THERAPEUTICS INC | $2.3M | 1.84% | 1,200,000 | Common | SOLE |
| G4444H101 | BBOT | HELIX ACQUISITION CORP II | $1.9M | 1.53% | 180,945 | Common | SOLE |
| 00445A100 | — | ACELYRIN INC | $1.8M | 1.45% | 364,000 | Common | SOLE |
| 28036F105 | EWTX | EDGEWISE THERAPEUTICS INC | $1.7M | 1.36% | 63,000 | Common | SOLE |
| 26818M108 | DYN | DYNE THERAPEUTICS INC | $1.7M | 1.34% | 46,200 | Common | SOLE |
| 375558103 | GILD | GILEAD SCIENCES INC | $1.6M | 1.32% | 19,500 | Common | SOLE |
| 90400D108 | RARE | ULTRAGENYX PHARMACEUTICAL INC | $1.4M | 1.13% | 25,100 | Common | SOLE |
| 89532M101 | TRVI | TREVI THERAPEUTICS INC | $970,270 | 0.79% | 290,500 | Common | SOLE |
| 90466Y103 | — | UNICYCIVE THERAPEUTICS INC | $807,315 | 0.65% | 1,979,199 | Common | SOLE |
| 53635D202 | LQDA | LIQUIDIA CORPORATION | $735,000 | 0.60% | 73,500 | Common | SOLE |
| 92539P101 | — | VERVE THERAPEUTICS INC | $707,124 | 0.57% | 146,100 | Common | SOLE |
| 374163103 | GERN | GERON CORP | $703,246 | 0.57% | 154,900 | Common | SOLE |
| 15102K100 | CELC | CELCUITY INC | $694,806 | 0.56% | 46,600 | Common | SOLE |
| 04317A107 | ARTV | ARTIVA BIOTHERAPEUTICS INC | $679,800 | 0.55% | 44,000 | Common | SOLE |
| 878972108 | TECX | TECTONIC THERAPEUTIC INC | $415,110 | 0.34% | 13,700 | Common | SOLE |
| 21833P301 | CRBP | CORBUS PHARMACEUTICALS HOLDINGS | $381,655 | 0.31% | 18,500 | Common | SOLE |
| 75383L102 | RAPP | RAPPORT THERAPEUTICS INC | $360,448 | 0.29% | 17,600 | Common | SOLE |
| 52187K200 | CYPH | LEAP THERAPEUTICS INC | $309,685 | 0.25% | 120,500 | Common | SOLE |
| 28658R106 | CLYM | CLIMB BIO INC | $274,860 | 0.22% | 54,000 | Common | SOLE |
| 08205P209 | BNTC | BENITEC BIOPHARMA INC | $273,862 | 0.22% | 29,800 | Common | SOLE |
| 89422G107 | TVTX | TRAVERE THERAPEUTICS INC | $265,810 | 0.22% | 19,000 | Common | SOLE |
| 88427A107 | — | THIRD HARMONIC BIO INC | $210,133 | 0.17% | 15,508 | Common | SOLE |
| 67080N119 | NUVB/WS | NUVATION BIO INC -CW27 | $8,892 | 0.01% | 90,832 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.